Nektar Therapeutics
NKTR
125 hedge funds and large institutions have $67.7M invested in Nektar Therapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 46 reducing their positions, and 25 closing their positions.
100% more call options, than puts
Call options by funds: $6K | Put options by funds: $3K
0.84% less ownership
Funds ownership: 5.02% → 4.19% (-0.84%)
9% less funds holding
Funds holding: 138 → 125 (-13)
21% less capital invested
Capital invested by funds: $85.3M → $67.7M (-$17.7M)
35% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 46
44% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.72M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.1M |
| 3 |
Renaissance Technologies
New York
|
+$918K |
| 4 |
MAM
Monaco Asset Management
Monaco
|
+$588K |
| 5 |
Millennium Management
New York
|
+$205K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.1M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.13M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.04M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.02M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$906K |
NKTR Hedge Fund Activity: Q4 2023 in Review
125 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2023, worth a combined $67.7M — down 21% from $85.3M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of NKTR and 14 opened new positions — a net loss of 11 holders — while 46 trimmed existing stakes and 30 added.
The largest buyer was GSA Capital Partners, adding an estimated $1.72M. The largest seller was RA Capital Management, exiting entirely with an estimated $11.1M sold.
- 125 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2023, down from 138 in Q3 2023.
- Funds reported $67.7M of Nektar Therapeutics stock for Q4 2023, down 21% quarter-over-quarter.
- 14 funds opened new Nektar Therapeutics positions in Q4 2023 and 25 closed out, a net change of -11 holders.
- The largest Nektar Therapeutics buyer in Q4 2023 was GSA Capital Partners, an estimated $1.72M added.
- The largest Nektar Therapeutics seller in Q4 2023 was RA Capital Management, an estimated $11.1M sold.
Based on aggregated 13F filings for Q4 2023.